Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
CMCO Columbus McKinnon Corp
PPBI Pacific Premier Bancorp Inc
CAT Caterpillar Inc
JHI John Hancock Investors Trust
SLGN Silgan Holdings Inc
GBX Greenbrier Companies Inc
GOOG Alphabet Inc
PUCKU Goal Acquisitions Corp
PRGO Perrigo Company PLC
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Closing Price
$766.39
Day's Change
5.15 (0.68%)
Bid
--
Ask
--
B/A Size
--
Day's High
769.00
Day's Low
752.00
Volume
(Light)
Volume:
441,486

10-day average volume:
595,062
441,486
  • Prev Close
    761.24
  • Today's Open
    752.52
  • Day's Range
    752.00-769.00
  • Avg Vol (10-day)
    595.1K
  • Last (time)
    4:00p ET 12/02/22
  • Last (size)
    3
  • 52-Wk Range
    538.01 - 769.63
    LowHigh
  • (06/14/22 - 11/09/22)
    0.42%
  • 33.3%
  • Market Cap
    83.5B
  • Shares Outstanding
    108.9M
  • 47.40
  • 16.06x
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.2
  • 87.82
  • (% of float 11/15/22)
    1.69

Latest News

December 02, 2022
5:33 pm ET
MarketWatch
December 01, 2022
5:32 pm ET
MarketWatch
7:00 am ET
PR Newswire
November 30, 2022
8:05 am ET
PR Newswire
November 29, 2022
5:32 pm ET
MarketWatch
November 28, 2022
5:31 pm ET
MarketWatch
November 23, 2022
5:20 pm ET
MarketWatch
November 22, 2022
5:20 pm ET
MarketWatch
7:00 am ET
PR Newswire
November 21, 2022
5:20 pm ET
MarketWatch
November 18, 2022
5:19 pm ET
MarketWatch
November 17, 2022
5:20 pm ET
MarketWatch
7:00 am ET
PR Newswire
7:00 am ET
Globe Newswire
November 16, 2022
5:20 pm ET
MarketWatch
November 15, 2022
5:20 pm ET
MarketWatch
November 14, 2022
5:20 pm ET
MarketWatch
November 11, 2022
5:19 pm ET
MarketWatch
7:03 am ET
MarketWatch
6:59 am ET
PR Newswire
November 10, 2022
5:20 pm ET
MarketWatch
November 09, 2022
5:20 pm ET
MarketWatch
November 08, 2022
5:20 pm ET
MarketWatch
10:40 am ET
Zacks
November 07, 2022
5:20 pm ET
MarketWatch
November 04, 2022
5:20 pm ET
MarketWatch
November 03, 2022
5:20 pm ET
MarketWatch
4:05 pm ET
PR Newswire
9:00 am ET
PR Newswire
6:51 am ET
MarketWatch
6:35 am ET
MarketWatch
6:34 am ET
MarketWatch
6:34 am ET
MarketWatch
6:30 am ET
PR Newswire
November 02, 2022
5:20 pm ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.